Abstract Details

Title The Prevalence of Visual Snow and Visual Snow Syndrome in the Pediatric Population.

Topic Headache

Presentation(s) P11 - Poster Session 11 (8:00 AM-9:00 AM)

Poster/Presentation
Number 12-001

Objective To determine the prevalence of visual snow and visual snow syndrome in the pediatric population via an electronic survey.

Background Visual snow (VS) is the visual perception of enumerable tiny dots in the visual field resembling static on a television screen. If patients experience these symptoms >3 months, along with at least two other positive visual symptoms including palinopsia, entopic phenomenon, photophobia and nyctalopia, they meet criteria for visual snow syndrome (VSS). In previous studies on VS/VSS, many patients describe experiencing these symptoms “as long as they can remember” but the prevalence in children has yet to be elucidated. The goal of our study was to determine the prevalence of VS and VSS in the pediatric population.

Design/Methods 1600 children were surveyed using a 23-question online survey of VS/VSS symptoms and migraine symptoms based on ICHD-3 criteria. Recruitment: emails were sent to parents of children ages 5-17 seen in all pediatric patient visits from 1/2021-5/2024 at our institution with additional announcements in community advertisements and school flyers. Emails and announcements contained survey instructions/access.

Results Of the survey respondents, 1324 answered the requisite VS questions and were included in data analysis. 412/1324 (31%) reported seeing dots, and 135/1324 (10%, CI 8.6-12%) reported seeing dots “most/all the time” for >3 months (criteria for VS). Additionally, 590/1263 (46.7%) reported palinopsia; 221/1251 (17.7%) reported nyctalopia; almost one-fourth of children reported photophobia without headaches “always” 159/1251 (12.7%) or “a lot” of time 250/1251 (20%). In total, of the 1319 respondents, 114 (8.6%, CI 7.2-10.3%); met criteria for visual snow syndrome with a mean age 13.7 y.o. (SD = 3.2). Migraine was reported in 77% of patients with VS and 79% of those who met criteria for VSS.

Conclusions Based on our survey, the prevalence of VS in children aged 5-17 is 10% and the prevalence of VSS is 8.6%.

Authors/Disclosures
Brandon M. Jones, MD PRESENTER	Dr. Jones has nothing to disclose.
Paul E. Youssef, DO (Mayo Clinic)	Dr. Youssef has nothing to disclose.
Chia-Chun Chiang, MD (Mayo Clinic)	Dr. Chiang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Chiang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aruene Corporation . Dr. Chiang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Chiang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. Dr. Chiang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. The institution of Dr. Chiang has received research support from American Heart Association. The institution of Dr. Chiang has received research support from Lundbeck. The institution of Dr. Chiang has received research support from Pfizer.
Kenneth J. Mack, MD, PhD, FAAN	Dr. Mack has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Mack has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Mack has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AbbieVie. Dr. Mack has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Upsher Smith. Dr. Mack has received publishing royalties from a publication relating to health care.
Carrie E. Robertson, MD, FAAN (Mayo Clinic)	Dr. Robertson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbvie. Dr. Robertson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Linpharma. Dr. Robertson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Satsuma. Dr. Robertson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Robertson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Apeya. Dr. Robertson has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for UpToDate. The institution of Dr. Robertson has received research support from Biohaven/Pfizer. Dr. Robertson has received publishing royalties from a publication relating to health care. Dr. Robertson has received personal compensation in the range of $500-$4,999 for serving as a Research consultant with University of Minnesota.

��ɫ��

��ɫ��